These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 34846443)
1. Comparison of the uptake of untargeted and targeted immunostimulatory nanoparticles by immune cells in the microenvironment of metastatic breast cancer. Covarrubias G; Moon TJ; Loutrianakis G; Sims HM; Umapathy MP; Lorkowski ME; Bielecki PA; Wiese ML; Atukorale PU; Karathanasis E J Mater Chem B; 2022 Jan; 10(2):224-235. PubMed ID: 34846443 [TBL] [Abstract][Full Text] [Related]
7. Can targeted nanoparticles distinguish cancer metastasis from inflammation? Choi AS; Moon TJ; Abuhashim W; Bhalotia A; Qian H; Paulsen KE; Lorkowski M; Ndamira C; Gopalakrishnan R; Krishnamurthy A; Schiemann WP; Karathanasis E J Control Release; 2023 Oct; 362():812-819. PubMed ID: 37011838 [TBL] [Abstract][Full Text] [Related]
8. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Song Y; Tang C; Yin C Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030 [TBL] [Abstract][Full Text] [Related]
9. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy. Zhang R; Wan Y; Lv H; Li F; Lee CS J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052 [TBL] [Abstract][Full Text] [Related]
10. Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment. Lee S; Hong KH; Park H; Ha J; Lee SE; Park DJ; Jeong SD; Kim S; Kim D; Ahn J; Lee HW; Koh WG; Ha SJ; Kim YC J Control Release; 2024 Sep; 373():55-69. PubMed ID: 38971428 [TBL] [Abstract][Full Text] [Related]
12. Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy. Li JX; Shu N; Zhang YJ; Tong QS; Wang L; Zhang JY; Du JZ ACS Appl Mater Interfaces; 2024 May; 16(20):25665-25675. PubMed ID: 38735053 [TBL] [Abstract][Full Text] [Related]
13. An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment. Hsieh CH; Hsieh HC; Shih FS; Wang PW; Yang LX; Shieh DB; Wang YC Theranostics; 2021; 11(14):7072-7091. PubMed ID: 34093872 [TBL] [Abstract][Full Text] [Related]
14. Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity. Amini MA; Abbasi AZ; Cai P; Lip H; Gordijo CR; Li J; Chen B; Zhang L; Rauth AM; Wu XY J Natl Cancer Inst; 2019 Apr; 111(4):399-408. PubMed ID: 30239773 [TBL] [Abstract][Full Text] [Related]
15. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158 [TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
17. The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment. Becicka WM; Bielecki PA; Lorkowski ME; Moon TJ; Zhang Y; Atukorale PU; Covarrubias G; Karathanasis E Nanoscale Adv; 2021 Aug; 3(17):4961-4972. PubMed ID: 34485818 [TBL] [Abstract][Full Text] [Related]
18. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Yang M; Li J; Gu P; Fan X Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371 [TBL] [Abstract][Full Text] [Related]
19. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Chandra D; Quispe-Tintaya W; Jahangir A; Asafu-Adjei D; Ramos I; Sintim HO; Zhou J; Hayakawa Y; Karaolis DK; Gravekamp C Cancer Immunol Res; 2014 Sep; 2(9):901-10. PubMed ID: 24913717 [TBL] [Abstract][Full Text] [Related]
20. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Liao D; Liu Z; Wrasidlo WJ; Luo Y; Nguyen G; Chen T; Xiang R; Reisfeld RA Cancer Res; 2011 Sep; 71(17):5688-96. PubMed ID: 21784871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]